These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39158690)

  • 1. Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.
    Kole IH; Vural P; Yurdacan B; Alemdar A; Mutlu C
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1773-1785. PubMed ID: 39158690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
    Ramoz N; Boni C; Downing AM; Close SL; Peters SL; Prokop AM; Allen AJ; Hamon M; Purper-Ouakil D; Gorwood P
    Neuropsychopharmacology; 2009 Aug; 34(9):2135-42. PubMed ID: 19387424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD.
    Gul MK; Sener EF; Onal MG; Demirci E
    J Psychopharmacol; 2022 Jun; 36(6):715-722. PubMed ID: 33944622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.
    Yang L; Qian Q; Liu L; Li H; Faraone SV; Wang Y
    J Neural Transm (Vienna); 2013 Jul; 120(7):1127-33. PubMed ID: 23266789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
    Brown JT; Bishop JR
    Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
    Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
    Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
    Fu D; Guo HL; Hu YH; Chen F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by
    Chatterjee M; Saha S; Maitra S; Ray A; Sinha S; Mukhopadhyay K
    Drug Metab Pers Ther; 2023 Mar; 38(1):45-56. PubMed ID: 36169235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
    Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
    Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
    Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
    Brown JT; Abdel-Rahman SM; van Haandel L; Gaedigk A; Lin YS; Leeder JS
    Clin Pharmacol Ther; 2016 Jun; 99(6):642-50. PubMed ID: 26660002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
    Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
    CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.
    Kim BN; Kim JW; Hong SB; Cho SC; Shin MS; Yoo HJ
    Behav Brain Funct; 2010 Oct; 6():57. PubMed ID: 20929549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels.
    Demirci E; Sener EF; Gul MK; Onal MG; Dal F
    Eur J Clin Pharmacol; 2022 Jul; 78(7):1095-1104. PubMed ID: 35486119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A haplotype of the norepinephrine transporter gene (SLC6A2) is associated with visual memory in attention-deficit/hyperactivity disorder.
    Shang CY; Chiang HL; Gau SS
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():89-96. PubMed ID: 25554436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.